Trial reportJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2012
Characterisation of the contribution of the GABA-benzodiazepine α1 receptor subtype to [(11)C]Ro15-4513 PET images.
Trial report in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- GABAJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Article
- Glucose metabolism alterations and Aβ deposition in AD and FTD are related to the distribution of neurotransmitter systems.European journal of nuclear medicine and molecular imaging · 2026Article
- Machine learning to identify suitable boundaries for band-pass spectral analysis of dynamic [EJNMMI research · 2025Article
- GABAergic inhibition shapes behavior and neural dynamics in human visual working memory.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Article
- Erbb4 Deletion From Inhibitory Interneurons Causes Psychosis-Relevant Neuroimaging Phenotypes.Schizophrenia bulletin · 2023Article
- The effects of propofol anaesthesia on molecular-enriched networks during resting-state and naturalistic listening.NeuroImage · 2023Article
- Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- GABANeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- GABA-A receptor differences in schizophrenia: a positron emission tomography study using [Molecular psychiatry · 2021Article
- Αlpha 5 subunit-containing GABABrain communications · 2021Article
- Region-specific and dose-specific effects of chronic haloperidol exposure on [European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2020Article
- Model Comparison Metrics Require Adaptive Correction if Parameters Are Discretized: Proof-of-Concept Applied to Transient Signals in Dynamic PET.IEEE transactions on medical imaging · 2020Article
- Impaired theta phase coupling underlies frontotemporal dysconnectivity in schizophrenia.Brain : a journal of neurology · 2020Article
- Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity.Addiction biology · 2017Article
- Quantification of [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2017Article
- Test-retest reproducibility of quantitative binding measures of [NeuroImage · 2017Article
- Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism.NeuroImage · 2016Article
- Spectral Analysis of Dynamic PET Studies: A Review of 20 Years of Method Developments and Applications.Computational and mathematical methods in medicine · 2016Review
- Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors.Current topics in medicinal chemistry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
This positron emission tomography (PET) study aimed to further define selectivity of [(11)C]Ro15-4513 binding to the GABARα5 relative to the GABARα1 benzodiazepine receptor subtype. The impact of zolpidem, a GABARα1-selective agonist, on [(11)C]Ro15-4513, which shows selectivity for GABARα5, and the nonselective benzodiazepine ligand [(11)C]flumazenil binding was assessed in humans. Compartmental modelling of the kinetics of [(11)C]Ro15-4513 time-activity curves was used to describe distribution volume (V(T)) differences in regions populated by different GABA receptor subtypes. Those with low α5 were best fitted by one-tissue compartment models; and those with high α5 required a more complex model. The heterogeneity between brain regions suggested spectral analysis as a more appropriate method to quantify binding as it does not a priori specify compartments. Spectral analysis revealed that zolpidem caused a significant V(T) decrease (~10%) in [(11)C]flumazenil, but no decrease in [(11)C]Ro15-4513 binding. Further analysis of [(11)C]Ro15-4513 kinetics revealed additional frequency components present in regions containing both α1 and α5 subtypes compared with those containing only α1. Zolpidem reduced one component (mean±s.d.: 71%±41%), presumed to reflect α1-subtype binding, but not another (13%±22%), presumed to reflect α5. The proposed method for [(11)C]Ro15-4513 analysis may allow more accurate selective binding assays and estimation of drug occupancy for other nonselective ligands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.